SCHEMBL16096852

SCHEMBL16096852

Cc1ccc(N2CCNC(c3ccccc3)C2)cc1Cl

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 1/20 0.44
GSK3B P49841 2/20 0.43
KHK P50053 1/20 0.42
ADRB1 P08588 2/20 0.40
MAPT P10636 2/20 0.39
ALDH1A1 P00352 1/20 0.39
GFER P55789 1/20 0.39
PRKCQ Q04759 2/20 0.39
PRKCD Q05655 1/20 0.39
TP53 P04637 1/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
LMNA P02545 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
RPS6KB1 P23443 1/20 0.38
BCL2A1 Q16548 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8108419 0.80 BCL2A1 (0.54) KHKADRB1MAPTALDH1A1GFER
SCHEMBL2708307 0.80 ADRB1 (0.50) PDE10AGSK3BKHKADRB1ALDH1A1
SCHEMBL3273817 0.76 GSK3B (0.46) PDE10AGSK3BADRB1RPS6KB1
SCHEMBL28597182 0.76 ADRB1 (0.45) PDE10AGSK3BKHKADRB1MAPT
SCHEMBL3273814 0.76 GSK3B (0.46) PDE10AGSK3BADRB1RPS6KB1
SCHEMBL18617279 0.75 KHK (0.47) PDE10AGSK3BKHKPRKCQPRKCD
SCHEMBL17504935 0.73 NR1H2 (0.56)
SCHEMBL17504922 0.73 NR1H2 (0.56)
SCHEMBL20671922 0.73 PDE10A (0.41) PDE10AGSK3BKHKADRB1PRKCQ
SCHEMBL2984679 0.72 ADRB1 (0.73) ADRB1MAPTALDH1A1GFERTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10131637-B2 Anti-PCSK9 compounds and methods for the treatment and/or prevention of cardiovascular diseases SHIFA BIOMEDICAL CORPORATION (US) 2018-11-20 US disclosed
US-20180079730-A1 ANTI-PCSK9 COMPOUNDS AND METHODS FOR THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR DISEASES SHIFA BIOMEDICAL CORP (US) 2018-03-22 US disclosed
EP-2968318-A1 ANTI-PCSK9 COMPOUNDS AND METHODS FOR THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR DISEASES Shifa Biomedical Corporation (US) 2016-01-20 EP disclosed
US-20150376139-A1 ANTI-PCSK9 COMPOUNDS AND METHODS FOR THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR DISEASES NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-12-31 US disclosed
WO-2014150395-A1 ANTI-PCSK9 COMPOUNDS AND METHODS FOR THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR DISEASES SHIFA BIOMEDICAL CORPORATION (US) 2014-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180079730-A1 ANTI-PCSK9 COMPOUNDS AND METHODS FOR THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR DISEASES PCSK9, PCSK7, PCSK6 PDE10A 1852/4885GSK3B 73/4885KHK 686/4885
US-10131637-B2 Anti-PCSK9 compounds and methods for the treatment and/or prevention of cardiovascular diseases PCSK9, PCSK7, PCSK6 PDE10A 1561/4885GSK3B 117/4885KHK 1077/4885
US-20150376139-A1 ANTI-PCSK9 COMPOUNDS AND METHODS FOR THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR DISEASES PCSK9, PCSK7, PCSK6 PDE10A 1852/4885GSK3B 73/4885KHK 686/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.